Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sho Mitsuya"'
Autor:
Sho Mitsuya, MD, Masahiro Arai, MD, Kiyoe Kanaoka, MD, Tomoya Funamoto, MD, Hiroyuki Tsuji, MD, Kenjiro Tsuruoka, MD, PhD, Ninso Matsunaga, MD, Takahiko Nakamura, MD, Yosuke Tamura, MD, PhD, Masafumi Imanishi, MD, PhD, Soichiro Ikeda, MD, PhD, Akihisa Imagawa, MD, PhD, Yasuhito Fujisaka, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100631- (2024)
Osimertinib administration has been approved as an adjuvant treatment after complete surgical resection in patients with EGFR-mutated NSCLC. This article presents the first report of life-threatening postoperative osimertinib-induced interstitial lun
Externí odkaz:
https://doaj.org/article/26d3d531b4c84fe79dd21d8013090533
Autor:
Takahiko Nakamura, Kenjiro Tsuruoka, Kiyoe Kanaoka, Yosuke Tamura, Yasuhito Fujisaka, Soichiro Ikeda, Tomoya Funamoto, Masafumi Imanishi, Isao Goto, Akihisa Imagawa, Hiroyuki Tsuji, Sho Mitsuya, Ninso Matsunaga
Publikováno v:
Anticancer Research. 41:5137-5145
BACKGROUND For epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), administration of EGFR tyrosine kinase inhibitors (TKIs) is mandatory to prolong survival. To date, a comparison of second- and third-generation EGFR-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa4700940c7a872dbc66ac9176a43fc
https://doi.org/10.21873/anticanres.15331
https://doi.org/10.21873/anticanres.15331